Kalbe Genexine Biologics

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement initially struck with PT Kalbe Genexine Biologics (KGbio) in September 2019 regarding Henlius’s programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The Indonesian firm was initially granted rights to develop and commercialize the drug in certain Southeast…